NCT04256317 2026-03-18
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Phase 2/3 Recruiting
Clinical Trials
7 trialsNCT04708054 2026-02-19
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Phase 2/3 Recruiting
NCT06855810 2025-08-26
CCCG-TALL-2025
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT02416388 2024-08-07
BIG-1
University Hospital, Angers
Phase 2/3 Recruiting
NCT05939180 2024-04-09
VA vs DA for Newly Diagnosed Hig-risk AML
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT05805098 2023-04-07
VHA
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT05404906 2022-08-19
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting